Spots Global Cancer Trial Database for Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Official Title: Combination of Immune Checkpoint Inhibitors Tislelizumab and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Single-arm, Single-center, Phase 2 Clinical Study

Study ID: NCT05310383

Conditions

Recurrent Cervical Carcinoma

Metastatic Cervical Carcinoma

Persistent Cervical Carcinoma

Radiotherapy

Immunotherapy

Anti-programmed Cell Death Receptor 1

Immune Checkpoint Inhibitors

Tislelizumab

Objective Response Rate

Survival Outcomes

Interventions

Tislelizumab plus radiotherapy

Study Description

Brief Summary: This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer. Patients with platinum-resistant recurrent ovarian cancer who meet the inclusion criteria, and don't meet any of the exclusion criteria, are enrolled in the study. They will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles. Treatment continue until disease progression, intolerable toxicity, or patient refusal. Objective response rates primary objective. Progression-free survival, overall survival, and safety are secondary objectives. The study will enroll a total of 50 patients.

Detailed Description: